Verrica director granted 16,000 stock options

Verrica Pharmaceuticals Inc. director Lawrence Eichenfield received a grant of stock options covering 16,000 shares of common stock.

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. director Lawrence Eichenfield received a grant of stock options covering 16,000 shares of common stock. The options have an exercise price of $6.04 per share and expire on June 4, 2036.

These options vest in 12 equal monthly installments beginning on July 5, 2026 and are expected to be fully vested by the next annual meeting of stockholders, assuming he continues to serve as a director through each vesting date. Following this award, he holds 16,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 1 txn

Insider Eichenfield Lawrence

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	16,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 16,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.

Key Figures

Option grant size: 16,000 options Exercise price: $6.04 per share Expiration date: June 4, 2036 +3 more

6 metrics

Option grant size 16,000 options Stock Option (right to buy) granted to director

Exercise price $6.04 per share Exercise price of granted stock options

Expiration date June 4, 2036 Option expiration for director grant

Underlying shares 16,000 shares Common stock underlying the option grant

Vesting start July 5, 2026 First vesting date, then 12 equal monthly installments

Post-grant derivative holdings 16,000 options Total derivative securities held directly after transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, vest and become exercisable, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "6.0400" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-04T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"shares underlying this option shall vest and become exercisable in 12 equal monthly installments"

annual meeting of stockholders financial

"fully vested on the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Verrica Pharmaceuticals (VRCA) disclose in this Form 4?

Verrica disclosed that director Lawrence Eichenfield received a grant of stock options for 16,000 shares at an exercise price of $6.04, expiring June 4, 2036, as part of his director compensation.

How many Verrica (VRCA) stock options were granted to Lawrence Eichenfield?

Lawrence Eichenfield was granted stock options for 16,000 shares of Verrica common stock. These options give him the right to buy shares at a fixed $6.04 exercise price, subject to the vesting schedule disclosed.

What is the exercise price and expiration date of the new VRCA options?

The granted Verrica options have an exercise price of $6.04 per share and an expiration date of June 4, 2036. This means they can be exercised at $6.04 any time after vesting until that expiration date.

When do Lawrence Eichenfield’s Verrica (VRCA) options vest?

The options begin vesting on July 5, 2026, in 12 equal monthly installments. They will be fully vested by the date of Verrica’s next annual stockholder meeting, assuming Eichenfield continues serving as a director through each vesting date.

Is this Verrica (VRCA) Form 4 a stock purchase or an option grant?

This Form 4 reflects an option grant, not an open-market stock purchase. Eichenfield received stock options to buy 16,000 shares at $6.04, which vest over time rather than immediate ownership of common shares.

How many Verrica derivative securities does Lawrence Eichenfield hold after this grant?

After this grant, Eichenfield holds 16,000 derivative securities in the form of stock options. These options represent the right to acquire 16,000 shares of Verrica common stock once they vest and are exercised at $6.04 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eichenfield Lawrence

(Last) (First) (Middle)

C/O VERRICA PHARMACEUTICALS INC.

44 WEST GAY STREET, SUITE 400

(Street)

WEST CHESTER PENNSYLVANIA 19380

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.04	06/05/2026		A		16,000		(1)	06/04/2036	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.

	/s/ Lawrence Eichenfeld	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)